1. Home
  2. GORO vs GANX Comparison

GORO vs GANX Comparison

Compare GORO & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gold Resource Corporation

GORO

Gold Resource Corporation

HOLD

Current Price

$1.67

Market Cap

194.1M

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GORO
GANX
Founded
1998
2017
Country
US
US
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.1M
159.2M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
GORO
GANX
Price
$1.67
$1.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$1.75
$8.00
AVG Volume (30 Days)
10.5M
546.5K
Earning Date
04-16-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.95
EPS
N/A
N/A
Revenue
$65,726,000.00
$55,180.00
Revenue This Year
$9.04
N/A
Revenue Next Year
$93.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$1.41
52 Week High
$1.87
$4.34

Technical Indicators

Market Signals
Indicator
GORO
GANX
Relative Strength Index (RSI) 60.38 40.39
Support Level $1.54 $1.67
Resistance Level $1.70 $1.86
Average True Range (ATR) 0.13 0.13
MACD -0.01 0.04
Stochastic Oscillator 86.48 54.05

Price Performance

Historical Comparison
GORO
GANX

About GORO Gold Resource Corporation

Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: